Citations

Clear

3314 citation(s) found for "Do, Alexander".

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)
Broman, Kristy K. , Dossett, Lesly A. , Кириченко, Д. А. , Carr, Michael J. , Sharma, Avinash , Bartlett, Edmund K. , Nijhuis, Amanda A. G. , Kottschade, Lisa A. , Downs, Jennifer , Akkooi, Alexander C. J. van , Ollila, David W. , Frank, Jill S. , Karakousis, Giorgos C. , Nobes, Jenny , Vetto, John T. , Han, Dale , Farma, Jeffrey M. , Deneve, Jeremiah L. , Fleming, Martin D. , Bagge, Roger Olofsson , Lee, Ann Y. , Berman, Russell S. , Chai, Harvey , Kroon, Hidde M. , Teras, Jüri, Teras, Roland M., Hui, Jane Yuet Ching , Been, Lukas B. , Kruijff, Schelto , Naqvi, Syeda Mahrukh Hussnain , Sondak, Vernon K. , Broman, Kristy Kummerow , Kirichenko, Dennis , Bartlett, Edmund K , Hieken, Tina J , Kottschade, Lisa, Song, Yun , Karakousis, Giorgos , Lowe, Michael C , Hui, Jane Yuet Ching , Olofsson Bagge, Roger , Hughes, Tasha M. , Sun, James X. , Thompson, John F. , Hieken, Tina J. , Gyorki, David E. , Stahlie, Emma H. A. , Moncrieff, Marc D. , Perez, Matthew C , Mattsson, Jan , Farrow, Norma E. , Beasley, Georgia M. , Kim, Youngchul , Sarnaik, Amod A. , Zager, Jonathan S.

Mayo Clinic

Cancer | April 7, 2021 | Volume: 127 | Issue: 13 | Pages: 2251-2261

10.1002/cncr.33483 | PMID 33826754 Get It

BackgroundFor patients with sentinel lymph node (SLN)‐positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease‐specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown.MethodsIn a retrospective cohort of SLN‐positive adults treated at 21 institutions in Australia, Europe, and the United States from June 2017 to November 2019, the authors evaluated the impact of active surveillance and adjuvant therapy on all‐site recurrence‐free survival (RFS), isolated nodal RFS, distant metastasis‐free survival (DMFS), and DSS using Kaplan‐Meier curves and Cox proportional hazard models.ResultsAmong 6347 SLN biopsies, 1154 (18%) were positive and had initial negative distant staging. In total, 965 patients (84%) received active surveillance, 189 (16%) underwent CLND. Four hundred thirty‐nine patients received adjuvant therapy (surveillance, 38%; CLND, 39%), with the majority (83%) receiving anti–PD‐1 immunotherapy. After a median follow‐up of 11 months, 220 patients developed recurrent disease (surveillance, 19%; CLND, 22%), and 24 died of melanoma (surveillance, 2%; CLND, 4%). Sixty‐eight patients had an isolated nodal recurrence (surveillance, 6%; CLND, 4%). In patients who received adjuvant treatment without undergoing prior CLND, all isolated nodal recurrences were resectable. On risk‐adjusted multivariable analyses, CLND was associated with improved isolated nodal RFS (hazard ratio [HR], 0.36; 95% CI, 0.15‐0.88), but not all‐site RFS (HR, 0.68; 95% CI, 0.45‐1.02). Adjuvant therapy improved all‐site RFS (HR, 0.52; 95% CI, 0.47‐0.57). DSS and DMFS did not differ by nodal management or adjuvant treatment.ConclusionsActive surveillance has been adopted for most SLN‐positive patients. At initial assessment, real‐world outcomes align with randomized trial findings, including in adjuvant therapy recipients.Lay Summary For patients with melanoma of the skin and microscopic spread to lymph nodes, monitoring with ultrasound is an alternative to surgically removing the remaining lymph nodes. The authors studied adoption and real‐world outcomes of ultrasound monitoring in over 1000 patients treated at 21 centers worldwide, finding that most patients now have ultrasounds instead of surgery. Although slightly more patients have cancer return in the lymph nodes with this strategy, typically, it can be removed with delayed surgery. Compared with up‐front surgery, ultrasound monitoring results in the same overall risk of melanoma coming back at any location or of dying from melanoma.
Per pass analysis of thrombus composition retrieved by mechanical thrombectomy
Abbasi, Mehdi , Kvamme, Peter , Patel, Biraj M. , Gounis, Matthew J. , Kadirvel, Ramanathan , Kallmes, David F. , Doyle, Karen , Cloft, Harry J. , Liu, Yang , Thacker, Ike, Aghaebrahim, Amin, Sauvageau, Eric , Copelan, Alexander , Nazari, Pouya , Cantrell, Donald R. , Bhuva, Parita, Soomro, Jazba , Mohammaden, Mahmoud , Pisani, Leonardo , Puri, Ajit S , Brinjikji, Waleed , Patel, Biraj M , Fitzgerald, Seán , Mereuta, Oana M, Dai, Daying , Kadirvel, Ram , Kallmes, David F , Savastano, Luis E., Kayan, Yasha , Nazari, Pouya , Al-Bayati, Alhamza , Brinjikji, Waleed , Liu, Yang , Layton, Kennith F. , Hanel, Ricardó A. , Almekhlafi, Mohammed , Almandoz, Josser E Delgado , Mendes Pereira, Vitor , Jahromi, Babak S. , Yoo, Albert J. , Nogueira, Raul G. , Fitzgerald, Seán , Mereuta, Oana Madalina , Dai, Daying , Savastano, Luis , Demchuk, Andrew M. , Entwistle, John, Haussen, Diogo C , Al‐Bayati, Alhamza R , Rodrigues, Gabriel Martins

Mayo Clinic

Interventional Neuroradiology | April 7, 2021 | Volume: 27 | Issue: 6 | Pages: 815-820

10.1177/15910199211009119 | PMID 33823621 Get It

Background and aim Mechanical thrombectomy (MT) for large vessel occlusion often requires multiple passes to retrieve the entire thrombus load. In this multi-institutional study we sought to examine the composition of thrombus fragments retrieved with each pass during MT. Methods Patients who required multiple passes during thrombectomy were included. Histopathological evaluation of thrombus fragments retrieved from each pass was performed using Martius Scarlet Blue staining and the composition of each thrombus component including RBC, fibrin and platelet was determined using image analysis software. Results 154 patients underwent MT and 868 passes was performed which resulted in 263 thrombus fragments retrieval. The analysis of thrombus components per pass showed higher RBC, lower fibrin and platelet composition in the pass 1 and 2 when compared to pass 3 and passes 4 or more combined (P values <0.05). There were no significant differences between thrombus fragments retrieved in pass 1 and pass 2 in terms of RBC, WBC, fibrin, and platelet composition (P values >0.05). Similarly, when each composition of thrombus fragments retrieved in pass 3 and passes 4 or more combined were compared with each other, no significant difference was noted (P values >0.05). Conclusion Our findings confirm that thrombus fragments retrieved with each pass differed significantly in histological content. Fragments in the first passes were associated with lower fibrin and platelet composition compared to fragments retrieved in passes three and four or higher. Also, thrombus fragments retrieved after failed pass were associated with higher fibrin and platelet components.
Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802
Pidala, Joseph, Khera, Nandita , Howard, Alan , Wu, Juan , Bolaños-Meade, F. Javier, Ho, Vincent T. , Inamoto, Y., Arora, Mukta , Palmer, Jeanne , Lukez, Alexander , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Mayer, Sebastian , Renteria, Anne S. , Ayuk, Francis , Holler, Ernst , Efebera, Yvonne A. , Reantragoon, Rangsima , Yanik, Gregory A. , Ferrara, James L.M. , Holtan, Shernan G. , DeFor, Todd E. , Lee, Stephanie J. , Howard, Alan, Alousi, Amin Majid , Chen, George T , Flowers, Mary E.D. , Cutler, Corey S. , Wood, William A. , Hogan, William J. , Hexner, Elizabeth O. , Duong, Hien, Levine, John E. , Blazar, Bruce R. , Panoskaltsis‐Mortari, Angela , Weisdorf, Daniel J. , MacMillan, Margaret L.

Mayo Clinic

Blood | April 6, 2021 | Volume: 130 | Issue: Suppl_1 | Pages: 72-72

10.1182/blood.v130.suppl_1.72.72 Get It

Abstract Introduction: Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand that can restore integrity to damaged intestinal mucosa in murine models of acute graft-versus-host disease (aGVHD). We previously described AREG as a circulating biomarker of late-onset aGVHD, but its relevance combined with clinical risk factors has not yet been tested in a large cohort of patients with aGVHD occurring prior to day 100 post-transplant. We therefore tested samples from two aGVHD first-line treatment trials, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0302 and 0802, and identified a clinically relevant threshold level of circulating AREG at aGVHD onset. We then investigated whether incorporating AREG into the refined Minnesota Risk Score could further risk-stratify patients. Patients and Methods: Blood samples were obtained at the onset of systemic aGVHD treatment within BMT CTN 0302 (serum) and BMT CTN 0802 (plasma). All patients with response data and samples for analysis from both trials were included (N=251). We determined the association of AREG with clinical outcomes, including risk stratification by the refined Minnesota criteria, day 28 complete/partial response (CR/PR) to first-line therapy, 2-year overall survival (OS) and 6-month and 2-year non-relapse mortality (NRM). We investigated the effect of AREG on clinical endpoints per a doubling in the value of AREG, defined a clinically relevant threshold level in the AREG values using two-fold cross-validation, and confirmed the clinical relevance of this cut-point in independent samples (N=92) from pooled from drawn from the Chronic GVHD Consortium and the Mount Sinai Acute GVHD International Consortium (MAGIC). Results: In patients enrolled in BMT CTN 0302/0802, AREG levels were 1.7-fold higher in patients with Minnesota high-risk (HR) compared to standard-risk (SR) aGVHD (HR median 53.4 vs SR 31 pg/ml, p&lt;0.01). Every 2-fold increase in AREG was associated with a 33% decrease in the likelihood of day 28 CR/PR (odds ratio [OR] 0.67, p&lt;0.01, table). Clinical factors alone, as determined by the refined Minnesota Risk Score, were associated with day 28 CR/PR (p=0.02, table). Adding AREG to the Minnesota Risk Score could further risk-stratify patients. Minnesota SR patients with elevated AREG ≥ 33 pg/mL showed a 59% lower odds of day 28 CR/PR than SR patients with low AREG (OR 0.41, p=0.02). Patients with Minnesota HR aGVHD with AREG ≥ 33 pg/mL had the worst outcomes, with an 82% lower odds of day 28 CR/PR in comparison to HR with low AREG (OR 0.18, p&lt;0.01). High AREG was associated with worse OS and NRM in both Minnesota SR (hazard ratios 2-year OS 2.3, p&lt;0.01 and 6 month NRM 2.95, p=0.01, respectively) and HR patients (hazard ratios 2-year OS 3.35, p&lt;0.01 and 6-month NRM 9.38, p&lt;0.01 respectively, figure). Finally, in independent samples from the Chronic GVHD Consortium/MAGIC we confirmed that high AREG was associated with worse day 28 CR/PR (55.2% vs. 79.4%, p=0.02) and significantly worse 6-month survival after the onset of aGVHD (57.1% vs. 82.5%, p=0.01). Conclusion: AREG is elevated in patients with poor aGVHD outcomes and adds to the accuracy of risk stratification when combined with the refined Minnesota Risk Score. AREG ≥33 pg/mL at aGVHD onset is associated with lower day 28 CR/PR and higher mortality in samples from 4 multicenter cohorts. The mechanism of elevated circulating AREG in severe aGVHD is not yet known, although we hypothesize the degree of AREG elevation reflects the intensity of immune-mediated tissue injury resulting in AREG release. With accumulating evidence of altered EGFR ligands in aGVHD, further investigation into epithelial repair pathways involving AREG may lead to new adjunctive therapies to overcome poor steroid response in high-risk aGVHD. Disclosures Holtan: Incyte: Other: One-time advisory board member. Khera: Novartis: Consultancy. Lee: Mallinckrodt: Honoraria; Amgen: Other: One-time advisory board member; Bristol-Myers-Squibb: Other: One-time advisory board member; Kadmon: Other: One-time advisory board member. Chen: Immudex: Research Funding. Arora: Takeda Oncology: Consultancy. Flowers: Pharmacyclics: Consultancy. Cutler: Pfizer: Consultancy; Kite: Consultancy; Incyte: Consultancy; Bristol-Myers Squibb: Consultancy; Pharmacyclics: Consultancy; Astellas: Consultancy. Jagasia: Janssen: Consultancy, Research Funding; Therakos: Consultancy, Research Funding; Mallinckrodt: Consultancy. Hexner: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Levine: Novartis Pharmaceuticals Corporation: Membership on an entity's Board of Directors or advisory committees. MacMillan: Magenta Therapeutics: Research Funding.
Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study
Goswami, Julie , Tasson, Laurie Moon, Tischer, Alexander , Bailey, Kent R. , Spears, Grant M. , Dong, Jing-fei, Kozar, Rosemary A. , Park, Myung S., MacArthur, Taleen A. , Moon Tasson, Laurie, Auton, Matthew , Tischer, Alexander , Dong, Jing‐fei

Mayo Clinic

Trauma Surgery & Acute Care Open | April 5, 2021 | Volume: 6 | Issue: 1 | Pages: e000703

10.1136/tsaco-2021-000703 | PMID 33912688 Get It

Background Von Willebrand factor (VWF) is an acute phase reactant synthesized in the megakaryocytes and endothelial cells. VWF forms ultra-large multimers (ULVWF) which are cleaved by the metalloprotease ADAMTS-13, preventing spontaneous VWF–platelet interaction. After trauma, ULVWF is released into circulation as part of the acute phase reaction. We hypothesized that trauma patients would have increased levels of VWF and decreased levels of ADAMTS-13 and that these patients would have accelerated thrombin generation. Methods We assessed plasma concentrations of VWF antigen and ADAMTS-13 antigen, the Rapid Enzyme Assays for Autoimmune Diseases (REAADS) activity of VWF, which measure exposure of the platelet-binding A1 domain, and thrombin generation kinetics in 50 samples from 30 trauma patients and an additional 21 samples from volunteers. Samples were analyzed at 0 to 2 hours and at 6 hours from the time of injury. Data are presented as median (IQR) and Kruskal-Wallis test was performed between trauma patients and volunteers at both time points. Results REAADS activity was greater in trauma patients than volunteers both at 0 to 2 hours (190.0 (132.0–264.0) vs. 92.0 (71.0–114.0), p<0.002) and at 6 hours (167.5 (108.0–312.5.0) vs. 92.0 (71.0–114.0), p<0.001). ADAMTS-13 antigen levels were also decreased in trauma patients both at 0 to 2 hours (0.84 (0.51–0.94) vs. 1.00 (0.89–1.09), p=0.010) and at 6 hours (0.653 (0.531–0.821) vs. 1.00 (0.89–1.09), p<0.001). Trauma patients had accelerated thrombin generation kinetics, with greater peak height and shorter time to peak than healthy volunteers at both time points. Discussion Trauma patients have increased exposure of the VWF A1 domain and decreased levels of ADAMTS-13 compared with healthy volunteers. This suggests that the VWF burst after trauma may exceed the proteolytic capacity of ADAMTS-13, allowing circulating ULVWF multimers to bind platelets, potentially contributing to trauma-induced coagulopathy. Level of evidence Prospective case cohort study.
Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Floberg, John M. , Zhang, Jin , DeWees, T.A. , Inkman, Matthew , Chen, Kevin , Lin, Alexander J. , Rashmi, Ramachandran , Jayachandran, Kay , Edelson, Brian T. , Siegel, Barry A. , Dehdashti, Farrokh , Grigsby, Perry W. , Schwarz, Julie K. , DeWees, Todd A , Inkman, Matthew , Lin, Alexander J , Jayachandran, Kay , Siegel, Barry A , Dehdashti, Farrokh , Grigsby, Perry W , Schwarz, Julie K , Muhammad, Naoshad , Markovina, Stephanie T.

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 15 | Pages: 4245-4255

10.1158/1078-0432.ccr-20-4450 | PMID 33820781 Get It

Abstract Purpose: Chemoradiotherapy for locally advanced cervical cancer fails in over a third of patients. Biomarkers with therapeutic implications are therefore needed. We investigated the relationship between an established prognostic marker, maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography, and the inflammatory and immune state of cervical cancers. Experimental Design: An SUVmax most prognostic for freedom from progression (FFP) was identified and compared with known prognostic clinical variables in a cohort of 318 patients treated with definitive radiation with prospectively collected clinical data. Gene set enrichment analysis (GSEA) and CIBERSORT of whole-transcriptome data from 68 patients were used to identify biological pathways and immune cell subpopulations associated with high SUVmax. IHC using a tissue microarray (TMA, N = 82) was used to validate the CIBERSORT findings. The impact of macrophages on cervical cancer glucose metabolism was investigated in coculture experiments. Results: SUVmax &lt;11.4 was most prognostic for FFP (P = 0.001). The GSEA showed that high SUVmax is associated with increased gene expression of inflammatory pathways, including JAK/STAT3 signaling. CIBERSORT and CD68 staining of the TMA showed high SUVmax tumors are characterized by a monocyte-predominant immune infiltrate. Coculture of cervical cancer cells with macrophages or macrophage-conditioned media altered glucose uptake, and IL6 and JAK/STAT3 signaling contribute to this effect. Conclusions: SUVmax is a prognostic marker in cervical cancer that is associated with activation of inflammatory pathways and tumor infiltration of myeloid-derived immune cells, particularly macrophages. Macrophages contribute to changes in cervical cancer glucose metabolism. See related commentary by Williamson et al., p. 4136
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Shafique, Michael , Fisher, Terrence L. , Evans, Elizabeth E. , Leonard, John E. , Pastore, Desa Rae E. , Mallow, Crystal, Smith, Ernest, Mishra, Vikas , Schröder, Andreas , Chin, Kevin M. , Baumgart, Megan , Govindan, Ramaswamy , Gabrail, Nashat , Lou, Yanyan , Zauderer, Maurice , Shafique, Michael R , Beck, Joseph T , Baumgart, Megan A , Seetharamu, Nagashree , Mansfield, Aaron S , Sanborn, Rachel E , Goldman, Jonathan W , Govindan, Ramaswamy , Beck, J. Thaddeus , Spira, Alexander I. , Mansfield, Aaron S. , Goldman, Jonathan W.

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 13 | Pages: 3630-3640

10.1158/1078-0432.ccr-20-4792 | PMID 33820783 Get It

Abstract Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis
Kuhlman, Justin J. , Moustafa, Muhamad Alhaj , Tun, Alexander J., Menke, David M. , Jiang, Liuyan , Moustafa, Muhamad Alhaj , Tun, Han W. , Jiang, Liuyan , Kuhlman, Justin

Mayo Clinic

Clinical Case Reports | April 5, 2021 | Volume: 9 | Issue: 5 | Pages: No page available

10.1002/ccr3.3971 | PMID 34094552 Get It

AbstractEBV‐positive HHV8‐negative EBL is part of the spectrum of EBV‐positive diffuse large B‐cell lymphoma NOS. This entity can be labeled as primary age‐related EBV‐associated EBL and appears to respond well to rituximab and thoracentesis.
Effects of a 16-Week Multimodal Exercise Program on Physical Performance in Individuals With Dementia: A Multicenter Randomized Controlled Trial
Barisch‐Fritz, Bettina , Trautwein, Sandra , Scharpf, Andrea , Krell‐Roesch, Janina , Wöll, Alexander

Mayo Clinic

Journal of Geriatric Physical Therapy | April 4, 2021 | Volume: 45 | Issue: 1 | Pages: 3-24

10.1519/jpt.0000000000000308 | PMID 33813533 Get It

Background and Purpose: Dementia affects physical as well as cognitive performance. In individuals with dementia (IWD), decline in physical performance increases with disease progression and is associated with higher functional dependence and decreased quality of life. It is paramount to examine factors that potentially preserve physical performance in IWD, particularly in light of conflicting findings on the effectiveness of physical activity interventions on physical performance of IWD, mainly due to limited number of high-quality studies, large heterogeneity in methods used, or insufficient reporting of methods. The aim of this study was to investigate the effects of a 16-week multimodal exercise program (MEP) combining physical and cognitive tasks on physical performance in IWD, and to identify individual characteristics of MEP responders. Methods: A multicenter randomized controlled trial with assessment methods identified by an expert panel was conducted. We included 319 IWD of mild to moderate severity, older than 65 years, who underwent a standardized MEP specifically designed for IWD. At baseline and immediately after the MEP, we assessed physical performance (ie, mobility, balance, and strength) and function of lower extremities (primary outcomes). Potential effects of the MEP on physical performance were identified using 2-factor analyses of variance with repeated measurements within 2 samples (ie, intention-to-treat and per-protocol sample). Additionally, we compared characteristics related to physical performance between positive, non-, and negative responders. Results and Discussion: Neither analysis procedure revealed statistically significant time×group effects. However, 28% to 40% of participants were positive responders with regard to balance, and strength and function of lower extremities; and these persons had statistically significant lower baseline performance in the corresponding assessments. Conclusions: This randomized controlled trial revealed no overall effects of the MEP on physical performance, probably due to high heterogeneity of the study sample. Findings in responder analysis showed that IWD with lower physical performance at baseline tended to benefit more than those with higher baseline performance. Thus, a higher degree of individualization of the MEP depending on baseline performance on IWD may improve overall MEP effectiveness.
Automated identification of glomeruli and synchronised review of special stains in renal biopsies by machine learning and slide registration: a cross‐institutional study
Wilbur, David C. , Cornell, Lynn D. , Andryushkin, Alexander, Pettus, Jason R. , Cornell, Lynn , Smith, Maxwell L.

Mayo Clinic

Histopathology | April 4, 2021 | Volume: 79 | Issue: 4 | Pages: 499-508

10.1111/his.14376 | PMID 33813779 Get It

AimsMachine learning in digital pathology can improve efficiency and accuracy via prescreening with automated feature identification. Studies using uniform histological material have shown promise. Generalised application requires validation on slides from multiple institutions. We used machine learning to identify glomeruli on renal biopsies and compared performance between single and multiple institutions.Methods and resultsRandomly selected, adequately sampled renal core biopsy cases (71) consisting of four stains each (haematoxylin and eosin, trichrome, silver, periodic acid Schiff) from three institutions were digitised at ×40. Glomeruli were manually annotated by three renal pathologists using a digital tool. Cases were divided into training/validation (n = 52) and evaluation (n = 19) cohorts. An algorithm was trained to develop three convolutional neural network (CNN) models which tested case cohorts intra‐ and inter‐institutionally. Raw CNN search data from each of the four slides per case were merged into composite regions of interest containing putative glomeruli. The sensitivity and modified specificity of glomerulus detection (versus annotated truth) were calculated for each model/cohort. Intra‐institutional (3) sensitivity ranged from 90 to 93%, with modified specificity from 86 to 98%. Interinstitutional (1) sensitivity was 77%, with modified specificity 97%. Combined intra‐ and inter‐institutional (1) sensitivity was 86%, with modified specificity 92%.ConclusionsFeature detection sensitivity degrades when training and test material originate from different sites. Training using a combined set of digital slides from three institutions improves performance. Differing histology methods probably account for algorithm performance contrasts. Our data highlight the need for diverse training sets for the development of generalisable machine learning histology algorithms.
Association of Virtual Surgical Planning With External Incisions in Complex Maxillectomy Reconstruction
Moore, Eric J. , Price, Daniel L., Abel, Kathryn M. Van , Janus, J.R., Moore, Ethan , Martin, Eli, Morris, Johnathan M., Alexander, Amy E. , Janus, Jeffery R, Moore, Ethan T, Van Abel, Kathryn M , Price, Daniel L. , Martin, Eliot J., Morris, Johnathan M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 1, 2021 | Volume: 147 | Issue: 6 | Pages: 526

10.1001/jamaoto.2021.0251 | PMID 33792635 Get It